Names | |
---|---|
Preferred IUPAC name
Methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate | |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.163.930 |
EC Number |
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C16H15F3N2O4 | |
Molar mass | 356.301 g·mol−1 |
Insoluble | |
Solubility in other solvents | DMSO: 184 mg/mL; methanol and ethanol: 63 mg/mL |
Hazards | |
GHS labelling: | |
Warning | |
H315, H319 | |
P264, P280, P302+P352, P305+P351+P338, P321, P332+P313, P337+P313, P362 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Bay K8644 is a chemical compound that functions as an L-type calcium channel agonist. Bay K8644 is used primarily as a biochemical research tool for this effect.[2] It is a structural analog of nifedipine with positive inotropic activity, and as an aromatic it is highly lipid soluble.